IXUS or SPGM: Which is the Better International All-Cap ETF?

IXUS offers a lower 0.07% expense ratio and a higher 3.0% dividend yield versus SPGM’s 0.09% fee and 1.8% yield, while SPGM posted stronger 1-year and 5-year performance. SPGM has $1.5B in AUM versus $56.0B for IXUS, and the funds differ materially in exposure: SPGM is about 62% U.S. equities with a 25% technology tilt, while IXUS is entirely non-U.S. and leans 23% financials. The article is a comparative ETF review rather than a catalyst-driven event, so market impact is limited.

Analysis

The real signal here is not that one fund is “better,” but that the market is currently paying up for the cleaner proxy to non-U.S. equity beta while still rewarding U.S. tech exposure inside the global wrapper. SPGM’s superior medium-term tape likely reflects the ongoing premium for U.S. mega-cap growth, which means its outperformance is more a function of factor mix than superior international selection. IXUS, by contrast, is the purer play on global normalization: if the next leg of performance comes from a weaker dollar, easing real rates, or a broadening away from U.S. growth, its higher foreign cyclicals and financials mix should close some of the gap.

The second-order effect is that IXUS is effectively a levered bet on global earnings translation and capital return normalization in non-U.S. markets, especially Japan, Europe, and selected EM. A lower beta and higher dividend yield make it less sensitive to sharp risk-off episodes, but also mean it can lag in momentum-driven rallies unless foreign currencies and local rates cooperate. SPGM’s tech concentration gives it more upside if AI-led capex remains the dominant equity theme, but it also creates hidden overlap with crowded U.S. growth positioning; that makes the fund more vulnerable to any de-rating in long-duration equities over the next 3-6 months.

The consensus miss is that the choice here may be less about “global diversification” and more about whether investors want to own the U.S. exceptionalism factor through an ETF wrapper or intentionally diversify it away. The yield and valuation gap suggest IXUS is the better defensive ballast if earnings breadth outside the U.S. improves, while SPGM is the better momentum vehicle if U.S. tech keeps compounding. Near term, watch the dollar and global rate differentials: a USD rollover would be the cleanest catalyst for IXUS relative performance, while any growth scare or AI-capex pause would hit SPGM first.

Key Decisions for Investors

• Long IXUS / short SPGM for a 3-6 month mean-reversion trade if the dollar weakens or U.S. growth leadership broadens; target a 5-8% relative outperformance of IXUS, stop if mega-cap tech re-accelerates.
• Use IXUS as the defensive international sleeve in portfolios needing income and lower beta; the 3.0% yield provides better carry while waiting for FX and earnings translation to improve over the next 6-12 months.
• If maintaining U.S. growth exposure, prefer SPGM only as a satellite position, not a core global allocation; it is effectively a hidden tech factor bet, so size it with a 10-15% drawdown budget over a growth de-rating window.
• Pair IXUS with a short-duration U.S. equity index hedge to isolate non-U.S. beta; this should work best in a regime where real rates fall and leadership rotates away from long-duration U.S. growth.
• Add ASML and selected ex-U.S. semi exposure only on dips if the goal is to express the same theme through single names; they provide more torque than IXUS but carry materially higher idiosyncratic risk.